Vaxcyte Inc [PCVX] stock is trading at $64.83, up 3.66%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The PCVX shares have gain 2.32% over the last week, with a monthly amount drifted -9.48%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 2, April 2024, Vaxcyte to Present at the 23rd Annual Needham Virtual Healthcare Conference. In a post published today on Yahoo Finance, Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, announced today that Company management will participate in a fireside chat at the 23rd Annual Needham Virtual Healthcare Conference on Tuesday, April 9 at 12:45 p.m. ET / 9:45 a.m. PT.
From an analyst’s perspective:
Vaxcyte Inc [NASDAQ: PCVX] stock has seen the most recent analyst activity on December 07, 2023, when Mizuho initiated its Buy rating and assigned the stock a price target of $69. On January 03, 2023, Needham reiterated its Buy rating and revised its price target to $58 on the stock. Guggenheim started tracking the stock assigning a Buy rating and suggested a price target of $66 on December 15, 2022. BTIG Research initiated its recommendation with a Buy and recommended $69 as its price target on November 17, 2022.
Vaxcyte Inc [PCVX] stock has fluctuated between $34.11 and $82.04 over the past year. Currently, Wall Street analysts expect the stock to reach $63.25 within the next 12 months. Vaxcyte Inc [NASDAQ: PCVX] shares were valued at $64.83 at the most recent close of the market. An investor can expect a potential drop of -2.44% based on the average PCVX price forecast.
Analyzing the PCVX fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.28, Equity is -0.31 and Total Capital is -0.31. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.02.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 63.01 points at the first support level, and at 61.20 for the second support level. However, for the 1st resistance point, the stock is sitting at 65.96, and for the 2nd resistance point, it is at 67.10.
Ratios To Look Out For
For context, Vaxcyte Inc’s Current Ratio is 7.54. Further, the Quick Ratio stands at 7.54, while the Cash Ratio is 2.73.
Transactions by insiders
Recent insider trading involved Wassil Jim, CHIEF OPERATING OFFICER, that happened on Apr 01 ’24 when 3000.0 shares were sold. CHIEF EXECUTIVE OFFICER, PICKERING GRANT completed a deal on Apr 01 ’24 to sell 2616.0 shares. Meanwhile, SVP, GEN COUNSEL & CORP SEC Eydelman Mikhail sold 1667.0 shares on Apr 01 ’24.
